NSE filing, NSE: VALIANTORG. Summary written from the filing by ALFA Finder's alert engine.
Valiant Organics Ltd: key numbers
- Share price
- ₹456.20
- Market cap
- ₹1,279 Cr
- Revenue (annual)
- ₹738.8 Cr
- Net profit (annual)
- ₹33.24 Cr
- P/E (TTM)
- 23.6×Sector 34.1×
- Promoter holding
- 37.89%+0.02% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Valiant Organics Ltd
All →Valiant Organics Other Announcement
The company has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Valiant Organics Legal & Regulatory
Valiant Organics received an income tax rectification order for Assessment Year 2015-16, determining a net payable amount of ₹0.22 Crore.
- Value
- ₹0.22 Cr
Valiant Organics Investor Presentation: Key Takeaways
Valiant Organics presented its FY26 performance at the AGM, reporting Revenue of INR 739 Cr and EBITDA margin of 13.64%. The firm is shifting focus towards high-margin Benzene and Chlorophenol derivatives.
Valiant Organics Annual General Meeting
Valiant Organics held its 21st AGM on September 29, 2026, transacting various ordinary and special business items including re-appointments and material related party transaction approvals.
Valiant Organics Promoter Buying: ₹0 Cr
Promoter Vicky Hemchand Gala purchased 3,500 shares of Valiant Organics via a market transaction. This increases the promoter's stake by 0.01%.
- Value
- ₹0.00 Cr
- Promoter stake change
- +0.01%
Valiant Organics Promoter Buying: ₹0.13 Cr
Promoter Vicky Hemchand Gala acquired 3,500 shares of Valiant Organics Ltd via a market purchase. This increases the promoter's holding from 0.92% to 0.93%.
- Value
- ₹0.13 Cr
- Promoter stake change
- +0.01%
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.